Table 3. Grade ⩾3 adverse events.
| n (%) | Arm A: 840/420 mg pertuzumab, n=15 | Arm B: 840 mg q3w pertuzumab, n=15 |
|---|---|---|
|
Total number of patients with ⩾1 event |
14 (93.3) |
12 (80.0) |
|
Events occurring in ⩾3 patients overall | ||
| Neutropeniaa | 8 (53.3) | 5 (33.3) |
| Anaemia | 4 (26.7) | 4 (26.7) |
| Diarrhoea | 4 (26.7) | 4 (26.7) |
| Decreased appetite | 2 (13.3) | 5 (33.3) |
| Febrile neutropenia | 4 (26.7) | 2 (13.3) |
| Fatigue | 3 (20.0) | 2 (13.3) |
| Hypokalaemia | 1 (6.7) | 3 (20.0) |
| Hyponatraemia | 4 (26.7) | 0 (0.0) |
| Nausea | 3 (20.0) | 1 (6.7) |
| Stomatitis | 2 (13.3) | 2 (13.3) |
| Hypophosphataemia | 1 (6.7) | 2 (13.3) |
| Mucosal inflammation | 3 (20.0) | 0 (0.0) |
a
Covers terms ‘neutropenia' and ‘neutrophil count decreased'.